





Healthcare. We Care.

Building ABC - Aspen's Biological Capability

Aspen's Capabilities across the Vaccines Value Chain

Globally and especially in LMICs and across Africa



Aspen is a partner with demonstrated ability to adopt different technologies at speed and to international standard

Aspen is seeking to build a portfolio of vaccines (and other biologicals) utilising diverse technology platforms

Aspen has a substantial international footprint covering Africa, Asia, Europe and Oceania, in many countries being a leading manufacturer of medicines, including specialty sterile presentations

Aspen, since inception, has been a company committed to global health and equity, starting with accessible ARV supplies through to most recently supply COVID-19 vaccine

COVID19 has demonstrated the need for global sterile capacity, especially in Africa



ALICE Vial Filling/LYO

Capacity	Current	2023/4	2024/5	Total
Lines	2	1	2	5
2R vials (M)	90	60	120	270
Doses (5/vial, M)	450	300	600	1,350
Lyophilisation	2	1		3

The end state capacity is significant and will not only be a large contributor to global supply but will be extremely meaningful to meeting the needs of Africa and other LMIC's

Not just vials - Production Capabilities

50-100 Million Syringes available



2 BFS lines

1 Bag line



4 inspection lines


5 packaging lines



QA / QC

3 sterile filling lines





Aspen's Global Footprint



Offers and Asks

Aspen Offers

- Established capacity at scale
- Proven capability for technology partners
- Opportunity for innovators to continue to provide DS/DP
- SRA experience including biologicals and vaccines
- A portfolio in line with African Union, Africa CDC and PAVM priorities
- Options for emergency use vaccines
- An international commercialisation footprint

Aspen's Asks

- Consolidated African demand sustained over a 5 year time horizon
- Continental/regional and national procurement policies that mandate African manufacturing
- Funding to support 'at scale' pricing for a 5 year period but not at 'rent seeking' levels
- Recognition that African needs manufacturing expertise across the value chain ie not just end-end; input as well as later stage manufacture, and commercialisation should be valued
- Policies that support African manufacturer collaborations
- Trade policies that support cross border supply
- Harmonisation/mutual recognition of regulatory and release requirements

